Understanding the function of the protien could shed light on disease states involving inappropriate cell movement, such as cancer metastasis. The scientists at Boston Biomedical combined several techniques
According to the analysis by Medco Health Solutions, the number of younger adults aged 20-44 using ADHD medications more than doubled from 2000 to 2004, outpacing increases in
The antibiotic will be tested in adults and adolescents with throat infections and tonsillitis brought about by strep infections. Enrollment in the clinical trial is expected begin in
The trial design is currently being discussed with the FDA, with trial commencement expected to begin by the end of 2005. “We are very pleased to be selected
A program to develop recombinant vaccines for plague and botulinum neurotoxin serotypes A and B, and a program to develop a vaccine for Venezuelan equine encephalitis have received
Aventis’ main patent protection for Arava expired in September 2003 and a pediatric exclusivity on Arava expired in March 2004. There are other exclusivities related to the drug
The transaction provides MedImmune with three preclinical stage programs developing monoclonal antibodies that target the B-cell antigens CD19, CD20 and CD22. These antigens are believed to play important
This is the final milestone payment in Unigene’s exclusive US licensing agreement with Upsher-Smith. Fortical, Unigene’s first US product, was approved and launched last month and is currently
Vicuron is a biopharmaceutical company focused on the development of novel infection fighters for both hospital-based and community-acquired infections. Through the transaction, Pfizer has acquired two new product
The FDA recommendations were made under the special protocol assessment (SPA), a process in which the FDA evaluates phase III clinical trials and gives assurances that the design
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.